Back to medications
Medication monograph
brexucabtagene autoleucel
CAR-T Cell TherapiesImmunotherapyOncology TherapeuticsCD19-Directed Genetically Modified Autologous T-cell Immunotherapies
Clinical reference
Product monograph
TECARTUS- brexucabtagene autoleucel suspension
Brands & formulations
Family members
TECARTUS
Marketed200000000 CELLSINTRAVENOUSSUSPENSION[
"brexucabtagene autoleucel"
]
Product monograph TECARTUS
Marketed100000000 CELLSINTRAVENOUSSUSPENSION[
"brexucabtagene autoleucel"
]
Product monograph Classification
- Chemical class
- CAR-T Cell Therapies
- Clinical class
- Immunotherapy, Oncology Therapeutics
- Banks class
- CD19-Directed Genetically Modified Autologous T-cell Immunotherapies